Cipla Company Profile

✉ Email this page to a colleague

▶ Start for $1
Remove trial restrictions

CIPLA has ninety-two approved drugs.

There are six US patents protecting CIPLA drugs. There are twenty tentative approvals on CIPLA drugs.

There are thirty patent family members on CIPLA drugs in twenty-one countries and three hundred and ninety-nine supplementary protection certificates in seventeen countries.

International Patents:	30
US Patents:	6
Tradenames:	81
Ingredients:	81
NDAs:	92
Patent Litigation for Cipla:	See patent lawsuits for Cipla
PTAB Cases with Cipla as petitioner:	See PTAB cases with Cipla as petitioner

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipla	LEVALBUTEROL HYDROCHLORIDE	levalbuterol hydrochloride	SOLUTION;INHALATION	078171-003	Dec 13, 2013	AN	RX	No	No		See Plans and Pricing				See Plans and Pricing
Cipla Ltd	ZIDOVUDINE	zidovudine	SOLUTION;ORAL	077981-001	Jun 26, 2008	AA	RX	No	No		See Plans and Pricing				See Plans and Pricing
Cipla	PREGABALIN	pregabalin	CAPSULE;ORAL	212280-007	Jan 10, 2020	AB	RX	No	No		See Plans and Pricing				See Plans and Pricing
Cipla	CINACALCET HYDROCHLORIDE	cinacalcet hydrochloride	TABLET;ORAL	208915-002	Mar 8, 2018	AB	RX	No	No		See Plans and Pricing				See Plans and Pricing
Cipla	NEVIRAPINE	nevirapine	TABLET;ORAL	077956-001	May 22, 2012	AB	RX	No	No		See Plans and Pricing				See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
China	101868472	See Plans and Pricing
Eurasian Patent Organization	201070597	See Plans and Pricing
European Patent Office	3150617	See Plans and Pricing
Japan	2011219498	See Plans and Pricing
Cyprus	1118915	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0785926	08C0041	France	See Plans and Pricing	PRODUCT NAME: AMBRISENTAN; REGISTRATION NO/DATE: EU/1/08/451/001-004 20080421
0480717	C990009	Netherlands	See Plans and Pricing	PRODUCT NAME: MONTELUKASTUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER NATRII MONTELUKASTUM; NATL REGISTRATION NO/DATE: RVG 23164 AND RVG 23165 19981103; FIRST REGISTRATION: FI 12766 AND 12767 19970825
1411900	2011C/016	Belgium	See Plans and Pricing	PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
2340828	LUC00195	Luxembourg	See Plans and Pricing	PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123
1301519	CR 2016 00012	Denmark	See Plans and Pricing	PRODUCT NAME: TENOFOVIRALAFENAMID ELLER ET SALT ELLER SOLVAT DERAF, I SAERDELESHED TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/15/1061/001-002 20151123
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.